At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,430 enrolled
Drug / intervention
Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Observer-blind, Placebo Controlled, Multicenter Clinical Trial to Assess Herpes Zoster Recurrence and the Reactogenicity, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine (HZ/su) When Administered Intramuscularly on a 0 and 2 Month Schedule to Adults ≥50 Years of Age With a Prior Episode of Herpes Zoster
In Brief
A Phase 3 clinical trial evaluating Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) and Placebo for Herpes Zoster. Completed, enrolled 1,430 participants across 3 sites.
Detailed Summary
The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartSep 2019
Primary CompletionFeb 2024
TodayJul 2026
First PostedSep 16, 2019
Enrollment StartSep 17, 2019
Primary CompletionFeb 15, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 6.8 years ago
Interventions
Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)biological
2 doses of HZ/su vaccine were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
Placebodrug
2 doses of Placebo were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.